Expert Analysis: ASCO GI 2023

CME

CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 23, 2023

Expiration: March 22, 2024

Christopher H. Lieu
Christopher H. Lieu, MD
Rachna Shroff
Rachna Shroff, MD, MS

Activity

Progress
1
Course Completed
Introduction

In this activity, Christopher H. Lieu, MD, and Rachna Shroff, MD, MS, review key studies presented at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets also may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare provider, how many patients with GI cancers do you provide care for in a typical month?

Based on data presented at ASCO GI 2023 from the phase III SWOG 1815 trial, patients with which of the following types of advanced biliary tract cancers appeared to derive a survival benefit from first-line nab-paclitaxel plus gemcitabine/cisplatin vs gemcitabine/cisplatin alone?

A patient arrives in your care with HER2-positive, RAS wild-type metastatic colorectal cancer (mCRC) with a left-sided primary tumor. The patient has previously received 2 lines of treatment, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, and has experienced disease progression with both.

Which of the following treatment options is FDA approved for this patient population and could be considered for this patient as of this time (March 2023)?

Based on data presented at ASCO GI 2023 from the phase III SPOTLIGHT study, which of the following biomarkers would be predictive of survival benefit with first-line zolbetuximab plus chemotherapy for patients with advanced gastric/GEJ adenocarcinoma?